10 September 2018
A new report by visiongain forecasts that the global pharma contract sales market will generate $7.36 billion in 2020. That revenue prediction and others appear in Pharma Contract Sales Market 2016-2026: Revenue Forecasts for Outsourced Detailing, Including Teledetailing and eDetailing, as well as Medical Education and Sample Management Services. That study gains publication in March 2016. Visiongain is a business information publisher and consultancy in London, UK.
Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said:
“The pharmaceutical contract sales market consists of revenues achieved by CSOs (contract sales organisations), which assist other companies in the sales and marketing of products and services. Outsourcing medical sales offers many benefits to pharmaceutical companies, and contract sales is one of the fastest growing sectors of the overall pharmaceutical outsourcing market, driven by a range of factors including new technologies, sales models and drug launches. However, the market faces many challenges, including the declining access to doctors, patent expiries for leading products, and large companies choosing to retain sales activities in-house.”
Visiongain’s updated analysis provides multilevel revenue forecasts for the pharma contract sales market from 2016 to 2026.
First it shows revenue predictions to 2026 for seven submarkets:
• Contract detailing (personal promotion/field sales)
• Contract non-personal promotion, with further sub-forecasting for teledetailing, eDetailing and other selling operations
• Medical education services
• Sample management services.
In addition, there appear four revenue forecasts to 2026 for prominent therapeutic segments of the overall pharma contract sales market:
• Cardiovascular diseases
• Metabolic disorders
• Cancer treatments
• Other drugs (grouped prediction).
That investigation also shows revenue forecasts to 2026 for 11 national markets:
• Germany, UK, France, Italy and Spain
• China, India, Brazil and Russia.
Companies that new study assesses include Quintiles, inVentiv Health, UDG Healthcare and Publicis Touchpoint Solutions. Interviews with three organisations – OnCall, Apodi and Hilver – also appear.
Visiongain’s new report discusses forces stimulating revenue expansion over the next ten years, as well as forces restraining the CSO industry. Pharma Contract Sales Market 2016-2026 adds to visiongain’s analytical reports on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices. Their purpose is to help organisations assess the potentials of industries and markets.
ecent studies and expert opinion suggest that the asthma and COPD market is more segregated than previously believed.
19 March 2019
The intravenous route is the most commonly used route of administration owing to its high effectiveness during critical surgeries, its high adoption in hospitals, and availability of advanced intravenous drugs which cater the need of surgeons.
19 March 2019
With higher-cost therapies in development, combined with increasing burdens on healthcare budgets from ageing populations and rising disease incidence, market access is becoming more challenging in countries worldwide.
28 February 2019
The potential use of drug delivery technologies in product lifecycle management and the enhancement of drug efficacy in many therapeutic sectors will act as drivers for growth of the market over the coming decade.